Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial

Table 1

Baseline characteristics of all enrolled patients.

	Sirolimus group	Conventional group
	42	20
Sex (female/male)	34/8	17/3
Age (years),
Duration of disease (years), median (range)	5 (1-20)	6 (2-14)
DAS28,
TJC,
SJC,
ESR (mm/h),
Prednisone dose (mg/d),
Use of concomitant agents (no. of patients)
Methotrexate	3	5
Leflunomide	23	11
Hydroxychloroquine	10	4
Thalidomide	1	1